BMS Sees Zeposia As Safer Oral Option In Ulcerative Colitis
Efficacy Comparable To Gilead/Galapagos JAK Inhibitor Filgotinib
Bristol Myers Squibb reported detailed results from the Phase III TRUE NORTH study that show durable remissions in a patient population that switches therapies due to loss of response.
